The journal Frontiers in Bioengineering and Biotechnology has formally retracted a 2021 research study examining the therapeutic effects of mesenchymal stem cell extracellular vesicles on doxorubicin-induced heart failure.
According to the official retraction notice published in November 2026, concerns were raised following original publication regarding the integrity of images presented across the published figures.
During the inquiry, the authors were contacted and given the opportunity to respond to the identified image discrepancies. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies.
Following the conclusion of the inquiry, the formal retraction was approved by the Chief Executive Editor of Frontiers. Official communications regarding the decision and the authors’ opportunity to respond have been archived by the publisher as part of the formal case record. The editorial office stated that the retraction notice was received and accepted on October 22, 2026, before formal release in the journal’s Cell and Gene Therapy section.
The journal thanked the users on PubPeer for bringing the published article to its attention.
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
The retraction was approved by Frontiers in Bioengineering, Frontiers Media SA, Switzerland. Correspondence is directed to the Frontiers Editorial Office at research.integrity@frontiersin.org. The official citation record catalogues the retraction under volume fourteen, article identifier 2037783, following its formal acceptance on October 22, 2026, and subsequent release on November 19, 2026.
Under the publisher disclaimer, all assertions and claims expressed within the article belong solely to the contributing authors rather than representing the views of their affiliated organizations, the journal, its editors, or its peer reviewers. Additionally, the publisher explicitly notes that any commercial product evaluated or manufacturer claim cited is neither guaranteed nor endorsed.
Distribution of the document follows Creative Commons Attribution licensing standards. This license permits reproduction and dissemination across other forums only if the original authors and copyright holders receive proper attribution, the original journal publication is formally cited, and all actions fully comply with established academic practices and license terms.
Subject of Research: Retraction of scientific study on mesenchymal stem cell extracellular vesicles in heart failure
Article Title: Retraction: Extracellular vesicles derived from human umbilical cord mesenchymal stem cells protect against DOX-induced heart failure through the miR-100-5p/NOX4 pathway
Article References: Frontiers Editorial Office (2026). Retraction: Extracellular vesicles derived from human umbilical cord mesenchymal stem cells protect against DOX-induced heart failure through the miR-100-5p/NOX4 pathway. Frontiers in Bioengineering and Biotechnology, 14, Article 2037783. https://doi.org/10.3389/fbioe.2026.2037783
Image Credits: AI Generated
DOI: 10.3389/fbioe.2026.2037783
Keywords: Retraction, Frontiers in Bioengineering and Biotechnology, PubPeer, Image Integrity, Research Ethics, Extracellular Vesicles, Mesenchymal Stem Cells, Heart Failure, Doxorubicin, Cell and Gene Therapy, Scientific Integrity, Editorial Policy, Data Integrity, Post-Publication Review, Stem Cell Research
News Source: Gregory Coleman. (November 19, 2026). Frontiers Retracts 2021 Heart Failure Study Over Figure Integrity Concerns. Scienmag.



